Scholars@Duke
Rhonda L Bitting

Rhonda L Bitting

Associate Professor of Medicine
Medicine, Medical Oncology
rhonda.bitting@duke.edu
DUMC Box 103861, Durham, NC 27710
905 S LaSalle St, Rm 2052, Durham, NC 27710

Selected Publications

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal Article J Natl Compr Canc Netw · November 2025 The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer ... Full text Link to item Cite

Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey.

Journal Article JCO Precis Oncol · May 2025 PURPOSE: Genomic testing for prostate cancer (PCa) clinical management and hereditary cancer assessment has grown in clinical impact; however, challenges remain regarding optimal implementation and end-user confidence. The Decision-making, Experience, and ... Full text Link to item Cite

Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.

Journal Article Eur Urol Oncol · April 2025 BACKGROUND AND OBJECTIVE: Androgen deprivation therapy (ADT) with salvage radiation therapy (RT) improves survival for patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) for prostate cancer (PC), but many patients suf ... Full text Link to item Cite

Genomic classifiers and prognosis of localized prostate cancer: a systematic review.

Journal Article Prostate Cancer Prostatic Dis · March 2025 BACKGROUND: Refinement of the risk classification for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classifiers, Decipher, GPS, and Prolar ... Full text Link to item Cite

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline.

Journal Article J Clin Oncol · February 20, 2025 PURPOSE: To evaluate evidence on germline and somatic genomic testing for patients with metastatic prostate cancer and provide recommendations. METHODS: A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed ... Full text Link to item Cite

Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · February 10, 2025 154Background: In 2004, docetaxel (DOC), a semi-synthetic taxane, received regulatory approval for mCRPC based on improved ov ... Full text Cite

Major adverse cardiovascular events among Black and White Veterans receiving androgen deprivation therapy for prostate cancer: a retrospective cohort study.

Journal Article Cardiooncology · February 6, 2025 BACKGROUND: Androgen deprivation therapy (ADT) is the cornerstone treatment strategy for men diagnosed with high-risk prostate cancer (PC) but may increase risk for major adverse cardiovascular events (MACE). We examined whether men treated with ADT and ra ... Full text Link to item Cite

Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer : A Systematic Review.

Journal Article Ann Intern Med · February 2025 BACKGROUND: Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations. PURPOSE: To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris ... Full text Link to item Cite

Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · December 2024 BACKGROUND: Previous studies have shown that Black men receive worse prostate cancer care than White men. This has not been explored in metastatic castration-sensitive prostate cancer (mCSPC) in the current treatment era. METHODS: We evaluated treatment in ... Full text Link to item Cite

Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT Experience.

Journal Article Curr Oncol · August 21, 2024 The United States Veterans Affairs (VA) Health Care System has a strong history of conducting impactful oncology randomized clinical trials (RCTs). We developed a phase II/III RCT to test the use of metastasis-directed therapy in Veterans with oligometasta ... Full text Link to item Cite

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).

Journal Article J Clin Oncol · April 1, 2024 PURPOSE: Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, and abiraterone acetate plus prednisone (AAP) ... Full text Link to item Cite

NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.

Journal Article J Natl Compr Canc Netw · April 2024 The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summa ... Full text Link to item Cite

Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · March 1, 2024 BACKGROUND: Studies have shown improved survival among individuals with cancer with higher levels of social support. Few studies have investigated social support and overall survival (OS) in individuals with advanced prostate cancer in an international coh ... Full text Link to item Cite

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer.

Journal Article JCO Precis Oncol · March 2024 Clinical genomic testing of patient germline, tumor tissue, or plasma cell-free DNA can enable a personalized approach to cancer management and treatment. In prostate cancer (PCa), broad genotyping tests are now widely used to identify germline and/or soma ... Full text Link to item Cite

Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.

Journal Article Cancer Res Commun · February 26, 2024 PURPOSE: Single-agent checkpoint inhibition is effective in a minority of patients with platinum-refractory urothelial carcinoma; therefore, the efficacy of combining low-dose paclitaxel with pembrolizumab was tested. MATERIALS AND METHODS: This was a pros ... Full text Link to item Cite

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · October 2023 The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence an ... Full text Link to item Cite

Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial.

Journal Article JCO Precis Oncol · August 2023 PURPOSE: Men with rising prostate-specific antigen (PSA) after radical prostatectomy (RP) may progress despite radiation and androgen-deprivation therapy (ADT). Tissue-based transcriptomic signatures can identify who may benefit from a more aggressive syst ... Full text Link to item Cite

Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · June 2023 BACKGROUND: Home-based training increases accessibility to exercise and mitigates the side effects of hormone therapy for prostate cancer (PC). However, it is unknown if men with more advanced disease are willing to partake in such interventions. PURPOSE: ... Full text Link to item Cite

Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Conference Journal of Clinical Oncology · June 1, 2023 5016 Background: ADT with salvage RT improves survival for men with PSA recurrence after RP. For high risk PSA recurrence, current standard ADT duration is up to 2 years with RT; shortening but intensifying systemic therapy may i ... Full text Cite

Study design and methods for the pilot study of muscadine grape extract supplement to improve fatigue among older adult cancer survivors (FOCUS) trial.

Journal Article J Geriatr Oncol · May 2023 INTRODUCTION: Fatigue is a prevalent symptom among both cancer survivors and older adults. Negative consequences of fatigue include increased sedentary behavior, decreased physical activity and function, and lower quality of life. Few pharmacologic interve ... Full text Link to item Cite

NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.

Journal Article J Natl Compr Canc Netw · December 2022 The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reeval ... Full text Link to item Cite

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.

Journal Article J Immunother Cancer · August 2022 BACKGROUND: Phase 1/2 dose-escalation and expansion study evaluating varlilumab, a fully human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid tumors. METHODS: Phase 1 evaluated the safety of varlilumab (0.1-10 mg/kg) with niv ... Full text Link to item Cite

Impact of Race on Outcomes of High-Risk Patients With Prostate Cancer Treated With Moderately Hypofractionated Radiotherapy in an Equal Access Setting.

Journal Article Fed Pract · August 2022 BACKGROUND: Moderately hypofractionated radiotherapy (MHRT) is an accepted treatment for localized prostate cancer; however, limited MHRT data address high-risk prostate cancer (HRPC) and/or African American patients. We report clinical outcomes and toxici ... Full text Link to item Cite

Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors.

Journal Article JCO Precis Oncol · April 2022 PURPOSE: Poly ADP-ribose polymerase inhibitors (PARPi) are used for patients with advanced prostate cancer bearing alterations in homologous recombination repair (HRR) genes. We sought to characterize HRR gene variants and describe real-world outcomes for ... Full text Link to item Cite

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.

Journal Article Eur Urol Oncol · December 2021 BACKGROUND: Salvage external beam radiotherapy (RT) with androgen deprivation therapy (ADT) improves survival over RT in men with prostate cancer (PC) and rising prostate-specific antigen (PSA) levels after radical prostatectomy (RP). OBJECTIVE: To investi ... Full text Link to item Cite

Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · September 2021 BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer (PC) has detrimental effects on physical function and quality of life (QoL), but the addition of androgen receptor signalling inhibitors (ARSI) on these outcomes is unclear. PURPOSE: To com ... Full text Link to item Cite

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.

Journal Article Cancer · August 15, 2021 BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus prednison ... Full text Link to item Cite

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal Article J Immunother Cancer · August 2021 BACKGROUND: Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cyt ... Full text Link to item Cite

Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.

Journal Article Prostate Cancer Prostatic Dis · June 2021 BACKGROUND: Androgen-targeted therapy and chemotherapy are currently the mainstay of treatment in metastatic castration resistant prostate cancer (mCRPC). When progression occurs despite these therapeutic strategies, additional FDA-approved treatment optio ... Full text Link to item Cite

Phase I Study of Muscadine Grape Extract for Patients With Advanced Cancer.

Journal Article Am J Clin Oncol · June 1, 2021 OBJECTIVE: Preclinical studies with muscadine grape extract (MGE) show antitumor activity and decreased systemic inflammation. This phase I study (NCT02583269) assessed safety and tolerability of a proprietary MGE preparation in patients with advanced soli ... Full text Link to item Cite

Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Conference Journal of Clinical Oncology · February 20, 2021 90 Background: ADT with salvage RT improves survival for men with PSA recurrence after RP. Current standard duration of ADT for high risk PSA recurrence is up to 2 years with RT; therefore shortening but intensifying systemic the ... Full text Cite

Single-arm phase II study of low-dose paclitaxel and pembrolizumab in platinum-refractory metastatic urothelial carcinoma (UC).

Conference Journal of Clinical Oncology · February 20, 2021 433 Background: Single agent checkpoint inhibition is effective in a small proportion of platinum-refractory UC patients but improvements are needed. UC is highly inflammatory, and low-dose chemotherapy may enhance the response t ... Full text Cite

Racial Disparity in Response to Prostate Cancer Systemic Therapies.

Journal Article Curr Oncol Rep · July 23, 2020 PURPOSE OF REVIEW: In this review, we aim to describe racial differences in response to treatment for metastatic castration-resistant prostate cancer (mCRPC). RECENT FINDINGS: Recent data suggests that, despite higher risk features, African Americans may r ... Full text Link to item Cite

Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.

Journal Article Mol Carcinog · January 2020 Prostate cancer (PCa) deaths are typically the result of metastatic castration-resistant PCa (mCRPC). Recently, enzalutamide (Enz), an oral androgen receptor inhibitor, was approved for treating patients with mCRPC. Invariably, all PCa patients eventually ... Full text Link to item Cite

Trajectories in muscular strength and physical function among men with and without prostate cancer in the health aging and body composition study.

Journal Article PLoS One · 2020 OBJECTIVES: To examine and compare changes in strength and physical function from pre- to post-diagnosis among men with prostate cancer (PC, [cases]) and matched non-cancer controls identified from the Health, Aging and Body Composition (Health ABC) study. ... Full text Link to item Cite

A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).

Conference Journal of Clinical Oncology · May 20, 2019 TPS5097 Background: Androgen deprivation combined with salvage external beam radiation therapy (RT) have improved survival for patients (pts) with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP ... Full text Cite

Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.

Conference Journal of Clinical Oncology · March 1, 2019 29 Background: Salvage external beam radiotherapy (RT) and hormonal therapy improves survival over RT alone in men with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP). We investigated the safe ... Full text Cite

Phase I study of muscadine grape extract in advanced malignancy.

Conference Journal of Clinical Oncology · May 20, 2018 Full text Cite

Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.

Journal Article Biochim Biophys Acta Rev Cancer · April 2018 Traditional 2D cell cultures do not accurately recapitulate tumor heterogeneity, and insufficient human cell lines are available. Patient-derived xenograft (PDX) models more closely mimic clinical tumor heterogeneity, but are not useful for high-throughput ... Full text Link to item Cite

Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?

Journal Article Ann Oncol · February 1, 2018 Tissue biopsy is the standard diagnostic procedure for cancer. Biopsy may also provide material for genotyping, which can assist in the diagnosis and selection of targeted therapies but may fall short in cases of inadequate sampling, particularly from high ... Full text Link to item Cite

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

Conference Eur J Cancer · August 2017 BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single ar ... Full text Link to item Cite

Abstract 3187: Role of exosome secretion in the survival of enzalutamide-resistant prostate cancer cells: Syntaxin 6 as a novel therapeutic target

Conference Cancer Research · July 1, 2017 AbstractProstate cancer (PCa) is the most commonly diagnosed malignancy in the United States and remains the second leading cause of cancer deaths among American men. PCa deaths are typically the result of m ... Full text Cite

A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.

Conference Journal of Clinical Oncology · May 20, 2017 TPS2616 Background: FGFR inhibition is a promising and clinically proven therapeutic approach in a number of solid tumors where genetic alterations of FGFR drive oncogenesis. PRN1371 is a highly selective oral, irreversible inhib ... Full text Cite

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.

Journal Article J Hematol Oncol · May 4, 2017 BACKGROUND: Solid tumors residing in tissues and organs leave footprints in circulation through circulating tumor cells (CTCs) and circulating tumor DNAs (ctDNA). Characterization of the ctDNA portraits and comparison with tumor DNA mutational portraits ma ... Full text Link to item Cite

Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.

Journal Article Clin Cancer Res · March 1, 2017 Purpose: Beyond enumeration, circulating tumor cells (CTCs) can provide genetic information from metastatic cancer that may facilitate a greater understanding of tumor biology and enable a precision medicine approach.Experimental Design: CTCs and paired le ... Full text Link to item Cite

Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.

Journal Article Theranostics · 2017 Background: Cancers related to tobacco use and African-American ancestry are under-characterized by genomics. This gap in precision oncology research represents a major challenge in the health disparities in the United States. Methods: The Precision Oncolo ... Full text Link to item Cite

Clinical Characteristics of Patients With Renal Cell Carcinoma and Metastasis to the Thyroid Gland.

Journal Article Clin Med Insights Oncol · 2017 INTRODUCTION: Renal cell carcinoma (RCC) is the most common malignancy to metastasize to the thyroid gland. The aims of this study are as follows: (1) to analyze the clinical characteristics of patients with thyroid involvement of RCC and (2) in patients w ... Full text Link to item Cite

Pazopanib and Statin-Induced Rhabdomyolysis.

Journal Article Case Rep Oncol · 2017 BACKGROUND: The VEGF inhibitor pazopanib is a widely used first-line therapy for the treatment of advanced renal cell carcinoma. Potential drug-drug interactions and toxicities may be underrecognized. CASE PRESENTATION: A 73-year-old woman with metastatic ... Full text Link to item Cite

Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.

Journal Article Clin J Oncol Nurs · June 2015 BACKGROUND: Sipuleucel-T, an autologous cellular immunotherapy, is approved for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first personalized treatment for prostate cancer to be manuf ... Full text Link to item Cite

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Journal Article Urol Oncol · March 2015 BACKGROUND: The presence of ≥5 circulating tumor cells (CTCs) is prognostic for shorter survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, some men have low CTCs despite widespread disease, suggesting heterogeneity in CT ... Full text Link to item Cite

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Journal Article Cancer Metastasis Rev · September 2014 Nearly 30,000 men die annually in the USA of prostate cancer, nearly uniformly from metastatic dissemination. Despite recent advances in hormonal, immunologic, bone-targeted, and cytotoxic chemotherapies, treatment resistance and further dissemination are ... Full text Link to item Cite

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

Journal Article Clin Genitourin Cancer · August 2014 BACKGROUND: Vatalanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), whereas everolimus inhibits mammalian target of rapamycin (mTOR). Combination therapy with VEGFR and mTOR inhibitors has not been well tol ... Full text Link to item Cite

Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment.

Conference Journal of Clinical Oncology · February 1, 2014 178 Background: Serum alkaline phosphatase (AP) changes in men with metastatic prostate cancer have been described since the Nobel Prize winning discovery of the hormonal dependence of PC. High serum AP is independently associate ... Full text Cite

Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.

Conference Journal of Clinical Oncology · February 1, 2014 65 Background: Given the evolving treatments available in metastatic castration resistant prostate cancer (mCRPC), predictive biomarkers are desirable that maximize benefit and minimize harms and costs.The goal of this study was ... Full text Cite

Development of a method to isolate circulating tumor cells using mesenchymal-based capture.

Journal Article Methods · December 1, 2013 Epithelial tumor cells can become mesenchymal cells and vice versa via phenotypic transitions, a process known as epithelial plasticity. We postulate that during the process of metastasis, circulating tumor cells (CTCs) lose their epithelial phenotype and ... Full text Link to item Cite

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Journal Article Clin Genitourin Cancer · December 2013 BACKGROUND: Phosphatase and tensin homologue (PTEN) loss is common in advanced prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus blocks mammalian target of rapamycin (mTOR)/target of rapamycin complex 1 (TORC1), a ... Full text Link to item Cite

Identifying benchmarks for ASCO's "Choosing Wisely" measures that address low-value imaging in early-stage prostate and breast cancer.

Journal Article J Clin Oncol · November 2013 194 Background: ASCO has recently selected "Choosing Wisely" measures that identify physician health behaviors of low value in cancer care. Two of these measures address the use of advanced imaging for early stage disease. These measures aim to reduce imag ... Full text Link to item Cite

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

Journal Article Ann Oncol · July 2013 BACKGROUND: Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these agents and whether cross-resistance occurs is unknown. METHODS: Multicentre review ... Full text Link to item Cite

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

Journal Article Endocr Relat Cancer · June 2013 The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of t ... Full text Link to item Cite

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2013 105 Background: PTEN loss is common in advanced prostate cancer, leading to constitutive activation of the PI3 Kinase pathway. Temsirolimus blocks mTOR/TORC1, a key signaling node in this pathway; its activity in men with advance ... Full text Cite

Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.

Journal Article Cancer J · 2013 With the surge in therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specific treatments and ... Full text Link to item Cite

Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.

Journal Article Am Soc Clin Oncol Educ Book · 2012 With the surge in therapeutic options for castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specific treatments and accurate ... Full text Link to item Cite

Therapy for non-clear cell histologies in renal cancer.

Journal Article Curr Clin Pharmacol · August 2011 The advent of targeted systemic therapies has significantly improved treatment options for patients with metastatic renal cell carcinoma (RCC). Multiple agents that inhibit angiogenesis cell growth and proliferation via the VEGF and mTOR (TORC1) pathways h ... Full text Link to item Cite

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

Journal Article Mol Cancer Res · August 2011 During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial transitions (MET) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a precli ... Full text Link to item Cite

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Journal Article Clin Med Insights Oncol · 2011 Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food a ... Full text Link to item Cite

The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis.

Journal Article Blood Coagul Fibrinolysis · October 2009 The inhibition of factor VIII by autoantibody development, or acquired hemophilia, occurs in approximately one person per million each year and can cause life-threatening bleeding. Due to the disease rarity, there are no randomized studies addressing progn ... Full text Link to item Cite

Rapid measurement of total body water to facilitate clinical decision making in hospitalized elderly patients.

Journal Article J Gerontol A Biol Sci Med Sci · June 2009 BACKGROUND: Bioelectrical impedance analysis (BIA) is a noninvasive rapid and simple bedside technique that can be used to predict total body water (TBW), extracellular water (ECW), and intracellular water (ICW) and identify altered fluid distribution foll ... Full text Link to item Cite

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.

Journal Article Leuk Lymphoma · September 2007 Between January 1990 and April 2001, 115 patients received high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) for relapsed or refractory Hodgkin lymphoma (HL). With a median follow-up of 58 months (range, 1 - 175 months), ... Full text Link to item Cite

Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons.

Journal Article Ann Neurol · April 2002 Multiple gene defects cause Batten disease. Accelerated apoptosis accounts for neurodegeneration in the late infantile and juvenile forms that are due to defects in the CLN3 and CLN2 genes. Extensive neuronal death is seen in CLN2- and CLN3-deficient human ... Full text Link to item Cite